Merck Wins FDA Lipfendra Approval, Exoplanet Atmosphere Boosts Habitability Hope, Lifestyle Changes Prevent Dementia, Macrophage Therapy Slows Aging, and more...

Merck Wins FDA Lipfendra Approval, Exoplanet Atmosphere Boosts Habitability Hope, Lifestyle Changes Prevent Dementia, Macrophage Therapy Slows Aging, and more...

July 20, 2026 · 11 min

About this episode

This episode covers the FDA approval of Merck's Lipfendra, discoveries related to exoplanet atmospheres, dementia prevention strategies, macrophage therapy for aging, and the environmental impact of the Aral Sea's drying.

(0:10): FDA Approves Merck's Lipfendra, First Cholesterol-Lowering Pill, Offering Hope for High-Risk Patients (2:03): Discovery of Atmosphere on Rocky Exoplanet LHS 1140 b Boosts Hope for Habitability (4:19): WHO: Up to 45% of Dementia Cases Preventable with Lifestyle Changes (6:39): Targeted Macrophage Therapy Slows Aging, Improves Health in Mice: A Step Toward Human Applications (8:51): Aral Sea Drying Releases 748 Million Tons of CO2, Transforming Carbon Sink into Major Emissions Source To subscribe visit https://www.brief.news . For more updates in your inbox each morning visit www.brief.news . Image credit: WSOC TV

More episodes of Science News Daily

Explore listener stats, chart rankings, contacts and more on the Science News Daily podcast page.